Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5692)
  2. Department of Medicine (5682)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (200)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5692)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)
    Meeting Abstract

    Rappold, P. M.; Silagy, A. W.; Kuo, F.; Marker, M.; Reising, A.; Millholland, J.; Russo, P.; Coleman, J.; Voss, M. H.; Chan, T. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma
    Meeting Abstract

    Pal, S. K.; Albiges, L.; Rodriguez, C. S.; Liu, B.; Doss, J.; Khurana, S.; Scheffold, C.; Voss, M. H.; Choueiri, T. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer
    Meeting Abstract

    Patel, V. G.; Zhong, X.; Shah, N. J.; Martina, L. P.; Hawley, J.; Lin, E.; Gartrell, B. A.; Febles, V. R. A.; Wise, D. R.; Qin, Q.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR) - A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Josephson, D.; Carroll, P. R.; Wong, J. Y. C.; Pantel, A. R.; Cho, S. Y.; Gage, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Maruzzo, M.; Shah, A. Y.; Suarez, C.; Barrios, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Treatment results from a phase I study of WST11 phototherapy (VTP) for upper tract urothelial carcinoma
    Meeting Abstract

    Nogueira, L.; Tracey, A.; Alvim, R. G.; Reisz, P.; Sjoberg, D. D.; Demac, Q.; Benfante, N.; Nagar, K.; Thomas, J.; Cheng, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Mishra, A. A.; Bach, P. B.; Morris, M. J.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy
    Meeting Abstract

    Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy
    Meeting Abstract

    Motzer, R. J.; Liu, Y.; Perini, R. F.; Zhang, Y.; Heng, D. Y. C.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grunwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Kopyltsov, E.; Vidal, M. J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save